TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Persistent, Inadequately Controlled Allergic Asthma
Brief Summary: A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks. In patients with allergies, there is an exaggerated production of IgE in response to specific substances such as pollens. Omalizumab is a new drug that inactivates IgE. This study tested the safety and efficacy of omalizumab against asthma attacks in children with allergic asthma.


Options:
A: Arm Label: Mepolizumab IV; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab IV, Drug: SC Placebo | Arm Label: Mepolizumab SC; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab SC, Drug: IV Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo, Drug: SC Placebo | Intervention Type: DRUG; Name: Mepolizumab IV; Assigned to Arm(s): Mepolizumab IV | Intervention Type: DRUG; Name: Mepolizumab SC; Assigned to Arm(s): Mepolizumab SC | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): Mepolizumab SC, Placebo | Intervention Type: DRUG; Name: SC Placebo; Assigned to Arm(s): Mepolizumab IV, Placebo
B: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Drug: Fluticasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Fluticasone | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): Omalizumab, Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MEDI-563 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MEDI-563 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Comp. | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: MEDI-563; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MEDI-563; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo Comp.; Assigned to Arm(s): 4 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 5
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: IMA-026 | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: IMA-026; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Persistent, Inadequately Controlled Allergic Asthma
Brief Summary: A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks. In patients with allergies, there is an exaggerated production of IgE in response to specific substances such as pollens. Omalizumab is a new drug that inactivates IgE. This study tested the safety and efficacy of omalizumab against asthma attacks in children with allergic asthma.


Options:
A: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Drug: Fluticasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Fluticasone | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): Omalizumab, Placebo
B: Arm Label: Omalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Omalizumab (Xolair) + Conventional Therapy; Type: EXPERIMENTAL; Interventions: Biological: omalizumab | Arm Label: Placebo + Conventional Therapy; Type: PLACEBO_COMPARATOR; Interventions: Biological: omalizumab placebo | Intervention Type: BIOLOGICAL; Name: omalizumab; Assigned to Arm(s): Omalizumab (Xolair) + Conventional Therapy | Intervention Type: BIOLOGICAL; Name: omalizumab placebo; Assigned to Arm(s): Placebo + Conventional Therapy
D: Arm Label: Alair; Type: EXPERIMENTAL; Interventions: Device: Alair System | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Alair System | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Alair | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Sham

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Placebo Controlled Trial to Determine the Efficacy of Isoniazid (INH) in Preventing Tuberculosis Disease and Latent Tuberculosis Infection Among Infants With Perinatal Exposure to HIV
Brief Summary: Tuberculosis (TB) is highly endemic in sub-Saharan Africa. The increased burden of TB in settings with high prevalence of the Human Immunodeficiency Virus (HIV) is associated with high rates of transmission of Mycobacterium tuberculosis (M.tb) to both adults and children. Children infected with TB have a higher risk of developing severe disease than adults with TB. The purpose of this study was to determine if the antibiotic isoniazid (INH) prevented TB infection in infants born to HIV-infected mothers.


Options:
A: Arm Label: Continuous vs limited isoniazid; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Continuous vs limited isoniazid
B: Intervention Type: DRUG; Name: I ( isoniazid), II (isoniazid + rifampin ); Assigned to Arm(s): N/A
C: Arm Label: Daily Isoniazid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid (INH) daily for 9 months | Arm Label: Weekly Isoniazid / Rifapentine; Type: EXPERIMENTAL; Interventions: Drug: RPT + INH once weekly for 3 months given by DOT | Intervention Type: DRUG; Name: RPT + INH once weekly for 3 months given by DOT; Assigned to Arm(s): Weekly Isoniazid / Rifapentine | Intervention Type: DRUG; Name: Isoniazid (INH) daily for 9 months; Assigned to Arm(s): Daily Isoniazid
D: Arm Label: HIVneg/INH; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid (INH), Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX) | Arm Label: HIVneg/PL; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isoniazid Placebo (PL) | Arm Label: HIVpos/INH; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid (INH), Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX) | Arm Label: HIVpos/PL; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isoniazid Placebo (PL) | Intervention Type: DRUG; Name: Isoniazid (INH); Assigned to Arm(s): HIVneg/INH, HIVpos/INH | Intervention Type: DRUG; Name: Trimethoprim/Sulfamethoxazole (TMP/SMX); Assigned to Arm(s): HIVneg/INH, HIVpos/INH | Intervention Type: DRUG; Name: Isoniazid Placebo (PL); Assigned to Arm(s): HIVneg/PL, HIVpos/PL

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder
Brief Summary: This 24-week study will compare the safety and effectiveness of medication treatment alone (risperidone or aripiprazole) to medication treatment in combination with a parent management training program.


Options:
A: Arm Label: De Novo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Placebo; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Rollover Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): De Novo, Rollover Aripiprazole, Rollover Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314
C: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A
D: Arm Label: risperidone plus parent management training; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone, Behavioral: Behavior Therapy | Arm Label: risperidone only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone only, risperidone plus parent management training | Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): risperidone plus parent management training

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.


Options:
A: Arm Label: Youth-Nominated Support Team; Type: EXPERIMENTAL; Interventions: Behavioral: Youth-Nominated Support Team | Arm Label: Enhanced Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Youth-Nominated Support Team; Assigned to Arm(s): Youth-Nominated Support Team
B: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: venlafaxine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lithium; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Attachment-Based Family Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Attachment-Based Family Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine (Prozac) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus Treatment As Usual | Intervention Type: DRUG; Name: fluoxetine (Prozac); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo plus Treatment As Usual; Assigned to Arm(s): 2
B: Arm Label: Active, 1; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Active, 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Intervention Type: BEHAVIORAL; Name: Multifamily Psychoeducation Group (MFPG); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Treatment as usual (TAU); Assigned to Arm(s): 1, 2
D: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: venlafaxine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lithium; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.


Options:
A: Arm Label: TMS; Type: EXPERIMENTAL; Interventions: Device: Transcranial Magnetic Stimulation | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Transcranial Magnetic Stimulation - Sham Comparator | Intervention Type: DEVICE; Name: Transcranial Magnetic Stimulation; Assigned to Arm(s): TMS | Intervention Type: DEVICE; Name: Transcranial Magnetic Stimulation - Sham Comparator; Assigned to Arm(s): Sham
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: OPAC (Outreach, Problem solving, Adherence, Continuity) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: OPAC (Outreach, Problem solving, Adherence, Continuity); Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: venlafaxine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lithium; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A
D: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Evaluation of the Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients With Dyslipidemia (OCEANS)
Brief Summary: The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia).

At least 600 subjects with a similar medical condition will take part in this study.


Options:
A: Arm Label: ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe/simvastatin, Drug: Placebo for simvastatin 40 mg | Arm Label: simvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin, Drug: Placebo for simvastatin 40 mg, Drug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination | Intervention Type: DRUG; Name: ezetimibe/simvastatin; Assigned to Arm(s): ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): simvastatin | Intervention Type: DRUG; Name: Placebo for simvastatin 40 mg; Assigned to Arm(s): ezetimibe/simvastatin, simvastatin | Intervention Type: DRUG; Name: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination; Assigned to Arm(s): simvastatin
B: Arm Label: ER niacin/laropiprant; Type: EXPERIMENTAL; Interventions: Drug: ER niacin/laropiprant, Drug: simvastatin, Drug: ezetimibe/simvastatin | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin, Drug: ezetimibe/simvastatin | Intervention Type: DRUG; Name: ER niacin/laropiprant; Assigned to Arm(s): ER niacin/laropiprant | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): ER niacin/laropiprant, Placebo | Intervention Type: DRUG; Name: ezetimibe/simvastatin; Assigned to Arm(s): ER niacin/laropiprant, Placebo
C: Arm Label: Extended-release niacin; Type: EXPERIMENTAL; Interventions: Drug: extended-release niacin (Niaspan) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: extended-release niacin (Niaspan) | Intervention Type: DRUG; Name: extended-release niacin (Niaspan); Assigned to Arm(s): Extended-release niacin, Placebo
D: Intervention Type: DRUG; Name: Niacin Extended-Release and simvastatin Tablets; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)
Brief Summary: This randomized phase II trial studies how well celecoxib works in treating patients with cervical intraepithelial neoplasia, a precancerous lesion of the cervix which can develop into cervical cancer. Celecoxib may be effective in preventing the development of cervical cancer in patients who have cervical intraepithelial neoplasia.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Celecoxib | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™-based investigational formulation | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™-based investigational formulation; Assigned to Arm(s): Havrix Group
C: Arm Label: Arm I (celecoxib); Type: EXPERIMENTAL; Interventions: Drug: celecoxib | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): Arm I (celecoxib) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II (placebo)
D: Arm Label: Arm I (celecoxib); Type: EXPERIMENTAL; Interventions: Drug: Celecoxib, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): Arm I (celecoxib) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (celecoxib), Arm II (placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (placebo)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial
Brief Summary: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has sponsored a consortium of investigators to conduct a clinical treatment trial, Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY).

The primary objective of the TODAY trial is to compare the efficacy of three treatment arms on time to treatment failure based on glycemic control. The secondary aims are to:

* compare and evaluate the safety of the three treatment arms;
* compare the effects of the three treatments on the pathophysiology of type 2 diabetes (T2D) with regards to beta cell function and insulin resistance, body composition, nutrition, physical activity and aerobic fitness, cardiovascular risk factors, microvascular complications, quality of life, and psychological outcomes;
* evaluate the influence of individual and family behaviors on treatment response; and
* compare the relative cost effectiveness of the three treatment arms.

The three treatment regimens are: (1) metformin alone, (2) metformin plus rosiglitazone, and (3) metformin plus an intensive lifestyle intervention called the TODAY Lifestyle Program (TLP). The study recruits patients over a three-year period and follows patients for a minimum of two years. Patients are randomized within two years of the diagnosis of T2D.


Options:
A: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin (glucophage) | Arm Label: Oral Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: oral placebo | Intervention Type: DRUG; Name: Metformin (glucophage); Assigned to Arm(s): Metformin | Intervention Type: OTHER; Name: oral placebo; Assigned to Arm(s): Oral Placebo
B: Arm Label: Glucosanol; Type: ACTIVE_COMPARATOR; Interventions: Device: Glucosanol | Intervention Type: DEVICE; Name: Glucosanol; Assigned to Arm(s): Glucosanol
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Rosiglitazone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Program | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Lifestyle Program; Assigned to Arm(s): 3
D: Intervention Type: DRUG; Name: sibutramine; Assigned to Arm(s): N/A

Answer: C